FDA Expands Revlimid Label

Treatment approved for post-HSCT maintenance in multiple myeloma patients

The FDA has expanded the existing indications for lenalidomide (Revlimid, Celegen Corporation), a thalidomide analogue, to include use in patients with multiple myeloma as maintenance therapy after autologous hematopoietic stem-cell transplant (auto-HSCT). The expanded indication makes lenalidomide the only treatment to receive FDA approval for maintenance use following auto-HSCT.